Tyrer-Cuzick Breast Cancer Risk Calculator Explained

Imagine a doctor asks a simple question: if a plane had a 37 percent chance of crashing, would you board it? No one would. Yet that is the number Dr. Thais Aliabadi, an OB-GYN who has practiced in Los Angeles for three decades and says she has not lost a single patient to cancer in 25 years (00:54), found staring back at her from a computer screen in her own office. She was 48, with no family history of cancer, no genetic mutation, and none of the usual risk factors. An abnormal mammogram had led to a biopsy that came back with a finding called atypical cells, cells with the potential to turn cancerous but not yet cancer themselves (09:15). Out of curiosity, she reran her lifetime breast cancer risk score. It came back at 37 percent (09:35), more than triple the 12.5 percent average for American women (14:52).

"Mel, if I told you you were about to board a plane that had a 37% chance of crashing, would you board that plane?" (10:22) — Dr. Thais Aliabadi

Her colleagues called her paranoid. One surgeon told her, days before her double mastectomy, that she still disagreed with the decision. A week after the surgery, the pathology report came back: invasive cancer, found in the breast everyone had considered the safe one (11:29). Two weeks later, convinced something was still wrong, Aliabadi pushed for another MRI, over her own doctor's objections. A third radiologist finally confirmed what she suspected. Thirty-five percent of her breast tissue had been left behind after the first mastectomy (13:38). She underwent a second surgery six weeks later.

That story is the spine of this conversation with Mel Robbins, and it explains why Aliabadi spends the rest of the episode trying to make sure no other woman has to fight that hard to be believed.

"I'm here to scare you, because I want you... Unless I scare you, you won't be your own health advocate." (14:28) — Dr. Thais Aliabadi

The tool she credits with saving her life is called the Tyrer-Cuzick model, a formula that takes two minutes to fill out online: height, weight, breast density, menstrual and family history, prior biopsies (15:42). A score of 20 percent or higher puts a woman in the high-risk category, and Aliabadi starts those patients on breast imaging at age 30, not the standard 40 (16:00, 16:39). Crucially, a mammogram and an ultrasound alone are not enough for these women. They need an MRI added to the rotation, because mammograms struggle to distinguish cancer from dense breast tissue, a condition present in roughly half of all women (17:09, 18:25). The fix is a 3D mammogram, which gives radiologists a clearer look through that density (16:39).

Family history, it turns out, is a weaker predictor than most people assume. Eighty-five percent of women who develop breast cancer have no family history of the disease at all (21:41). Aliabadi herself is a case study: her standard genetic test came back negative. It was only after she underwent whole genome sequencing, a lab process that reads roughly 6.4 billion base pairs of DNA and screens for thousands of diseases, through a company called Simplified Genomics, that a different kind of risk showed up (19:30). She carries what is called a polygenic risk score, a pattern of many small genetic variants that individually mean little but together tripled her personal risk of breast cancer (21:18). For families with a known history of breast, ovarian, or pancreatic cancer, she recommends genetic testing for major mutations, there are 11 linked directly to breast cancer, by age 25 (22:04, 22:30).

Beyond the Breast

Aliabadi's most forceful recommendation may be the simplest: an annual pelvic ultrasound, for every woman, starting as soon as she becomes sexually active (32:50, 54:08). It is how she says she catches ovarian cancer at stage one or two, a disease notorious for reaching advanced stages before producing symptoms. Part of what makes this possible is a shift in where doctors now believe ovarian cancer actually starts. Research funded by the cancer foundation Breakthrough Cancer has found that somewhere between 65 and 85 percent of ovarian cancers originate not in the ovary itself but in the fallopian tube (34:19). Aliabadi described a patient, roughly 60 years old, with a history of endometriosis, who asked to have her tubes and ovaries removed as a precaution. The pathology came back with a 7 millimeter high-grade cancer in the fallopian tube (35:07). The surgery to remove tubes alone takes about 10 to 15 minutes laparoscopically (35:31, 35:46), and because the ovaries stay in place, a woman keeps her hormone production and does not enter surgical menopause (37:15). The exception is women carrying a BRCA mutation, who face a high enough lifetime ovarian cancer risk that Aliabadi recommends removing the ovaries as well, by age 40 (36:37).

The same yearly ultrasound also screens for uterine cancer, through a measurement of the endometrial lining. After menopause, Aliabadi wants that lining under 4 millimeters. A jump from a baseline of 3 millimeters to 7, even with no bleeding or symptoms, is enough to trigger a biopsy (38:41). Cervical cancer, she says, should not exist at all anymore. Nearly all cases start with HPV, a sexually transmitted virus, and regular Pap smears combined with HPV screening make it almost 100 percent preventable (40:15). The vaccine, now part of routine childhood immunization at ages 9 to 11, remains effective and recommended for adult women up to age 46 (41:10).

A Map for Every Decade

The back half of the conversation turns into something close to a checklist, organized by age. At 18 to 20, Aliabadi runs a baseline AMH test, a simple blood draw that measures anti-mullerian hormone and gives a read on ovarian reserve, the approximate supply of eggs remaining (48:21). By 25, she adds a full hormone panel and genetic testing if family history warrants it. By 30, every patient gets her lifetime breast cancer risk calculated. Between 28 and 32, she encourages patients without immediate plans for children to consider freezing eggs, since both egg count and quality decline with age, and the procedure can cost between $10,000 and $35,000 per cycle (49:58, 50:50). By 35, even low-risk patients get a baseline mammogram and ultrasound, and Aliabadi starts watching for perimenopause, which can begin 7 to 10 years before menopause itself. The average age of menopause is 51.5 years (51:15), meaning some women notice symptoms, irregular sleep, mood swings, hot flashes, joint pain, as early as their mid-30s (51:45).

At 45, she adds a baseline colonoscopy, moved earlier to 10 years before a relative's diagnosis age if there is a family history of colon cancer, along with a baseline bone density scan, because the steepest bone loss happens in the first five years after menopause (52:59, 53:21). Past 50, the well-woman exam should stop being just a Pap smear and a prescription refill and start addressing longevity directly. Aliabadi checks ApoE4, a genetic variant carried by 20 to 25 percent of women that raises Alzheimer's risk (55:21), and recommends that carriers start hormone replacement therapy within seven years of menopause, a window she says meaningfully lowers that risk (56:15). She also checks ApoB, a measure of the particles in blood that form arterial plaque, which she considers a better predictor of heart attack risk than standard LDL cholesterol alone (57:01). Her target is below 60, and ideally below 40 for patients aiming at a longer healthspan (57:53).

None of this requires a medical degree, Aliabadi says, only a willingness to walk into a 15-minute appointment with a written list and refuse to leave without answers.

"No one on this planet cares about your body or your health as much as you do. So you need to advocate for yourself." (59:18) — Dr. Thais Aliabadi

What makes her account persuasive is not just the data. It is the fact that she lived the failure mode herself, dismissed by colleagues who knew her, in a hospital system she had trained inside for decades. If a gynecologist with full access to every test in the book could still be waved off as anxious and paranoid, the odds are longer for everyone else. The remedy she offers is not more worry. It is a list of specific numbers, Tyrer-Cuzick score, breast density, AMH, ApoB, ApoE4, that turn a vague feeling of unease into a conversation a doctor cannot easily brush aside.